informative marker of disease burden or response to therapy in children and young adults with solid cancers.
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All patients provided a single baseline blood sample in EDTA. For patients receiving neoadjuvant chemotherapy, follow-up samples were requested every 4 hours after the start of chemotherapy until 24 hours had elapsed, and then daily if the patient was still admitted to the hospital. All samples were processed in the laboratory using only study ID numbers and assays were performed blinded to the study end point.
Samples were kept at 4°C until processing, usually within 15 minutes of sample collection. Peripheral blood was centrifuged at 2500 RPM for 15 minutes at 4°C. The plasma supernatant was removed and frozen at -80°C until all samples were available for analysis. At that time, the samples were thawed at 37°C for 15 minutes and analyzed within 4 hours of thawing. Samples and controls were analyzed according to the manufacturer recommendation using the Imuclone TM Annexin V ELISA assay (American Diagnostica, Inc). High value controls were 10.1-10.97 ng/mL and low values were 3.17-3.6 ng/mL, both within target ranges.
The initial study protocol was designed to enroll 15 patients based on the expected rate of newly diagnosed pediatric solid tumors at our institution over a 12-18 month enrollment period. After reviewing data from the first interim analysis of 9 patients, the study team determined that further evaluation of this putative biomarker was unlikely to be informative and enrollment ended.
Nine patients were enrolled, with clinical features shown in Table I . The mean baseline plasma annexin V level was 6.42 ng/mL (range 2.9-15.7 ng/mL). Only 3 of 9 subjects had plasma annexin V levels above the upper limit of 10 ng/mL at baseline. There was poor linear correlation between baseline plasma annexin V level and lactate dehydrogenase (LDH) (r=0.66; Tab. I).
We obtained plasma samples from 5 patients after the initiation of chemotherapy ( Fig. 1 ). Plasma annexin V did not reliably increase in these patients over the time course evaluated. Only 1 patient showed an increase in annexin V after initiation of chemotherapy to 9.3 ng/mL, which is still within the normal range.
To the Editors,
We are pleased to share the results of our pilot study evaluating plasma annexin V levels in children and young adults with solid cancers.
One of the earliest indicators of apoptosis, the process of programmed cell death, is externalization of cell membrane phosphatidylserine (1) . Annexin V is a cellular protein capable of binding with highaffinity to externalized phosphatidylserine. Annexin V staining has therefore become a standard approach for identifying cells undergoing apoptosis in vitro (1) .
Previous work has demonstrated that the annexin V protein can be measured in human plasma using enzyme-linked immunosorbent assay (ELISA) techniques. Healthy adults have been reported to have average plasma annexin V levels of 0.6-6.7 ng/mL (2) (3) (4) (5) . In almost all studies, healthy volunteers consistently have plasma annexin V levels less than 10 ng/mL. Further studies have shown increased plasma annexin V in patients with trauma, cardiac arrest, stroke, systemic lupus erythematosis, and primary antiphospholipid antibody syndrome (2, 3, 5, 6) .
Aside from 3 patients with lung or renal cancer, reported to have increased plasma annexin V levels, no other published reports have described plasma annexin V levels in patients with cancer (2) . We therefore initiated this study to determine if children and young adults with newly diagnosed solid tumors have elevated levels of plasma annexin V and to describe changes in these levels after starting chemotherapy. Our hypothesis was that plasma annexin V levels would be elevated at baseline and then increase in response to chemotherapy which would reflect apoptotic activity, increased cell lysis, or both.
Patients between 1 and 30 years of age were eligible for our study if they had a newly diagnosed, untreated primary solid cancer, excluding lymphoma. Patients were excluded if they had a known inherited or acquired hemolytic anemia, received a blood transfusion within 15 days of study entry or if transfusion was anticipated within 24 hours after study entry as these factors can increase plasma annexin V levels.
All participants or legal guardians provided consent for study participation, with assent obtained as
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DOI: 10.5301/JBM.2012.9288 adults with acute myocardial infarction noted 3 patients from the control group who had elevated levels and an underlying cancer diagnosis (2) . An additional 21 patients with cancer in the control group did not have elevated annexin V levels, which is consistent with our findings. It remains unknown if plasma annexin V would be a useful marker in patients with hematologic malignancies.
While the current study is limited in size, our early null results suggested that enrollment of additional subjects would not provide additional meaningful data. We conclude that plasma annexin V is not an Our study, the first to evaluate plasma annexin V levels systematically in patients with cancer, indicates that levels of this protein are not typically elevated in children with solid tumors at initial presentation. In addition, plasma annexin V levels did not increase in response to chemotherapy. These results refute our hypothesis that annexin V levels would be elevated at baseline and then increase in response to chemotherapy.
Based on these results, plasma annexin V will not provide a more precise surrogate marker of cell burden and turnover than the currently accepted marker, LDH (7, 8) . A previous study evaluating annexin V levels in 
